• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2011 - Product Image

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2011

  • ID: 1931529
  • September 2011
  • 71 pages
  • Global Markets Direct

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2011', provides an overview of the Non-Alcoholic Steatohepatitis therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis. 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Non-Alcoholic Steatohepatitis.
- A review of the Non-Alcoholic READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Non-Alcoholic Steatohepatitis Overview
Therapeutics Development
An Overview of Pipeline Products for Non-Alcoholic Steatohepatitis
Non-Alcoholic Steatohepatitis Therapeutics under Development by Companies
Non-Alcoholic Steatohepatitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Non-Alcoholic Steatohepatitis Therapeutics - Products under Development by Companies
Non-Alcoholic Steatohepatitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Non-Alcoholic Steatohepatitis Therapeutics Development
Mochida Pharmaceutical Co., Ltd.
Norgine Limited
Enzo Biochem, Inc.
Immuron Limited
Phynova Group Ltd
Raptor Pharmaceuticals Corp.
7TM Pharma A/S
Wellstat Therapeutics Corporation
Conatus Pharmaceuticals Inc.
Obio Pharmaceutical Holdings Limited.
Kalypsys, Inc.
NasVax Ltd.
Galmed International Ltd.
Connexios Life Sciences Pvt. Ltd.
Non-Alcoholic Steatohepatitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MND-21 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TM38837 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PYN22 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PN2XXX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KD3010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aramchol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EGS21 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AK20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cysteamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-3491390 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metreleptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Losartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Colesevelam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Opti-EPA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Hepato Protection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Silymarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral Anti-aCD3 Mab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxiphylline + Vitamin E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNX-FC010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Non-Alcoholic Steatohepatitis Therapeutics – Drug Profile Updates
Non-Alcoholic Steatohepatitis Therapeutics - Discontinued Products
Non-Alcoholic Steatohepatitis - Featured News
Mar 28, 2011: Intercept To Collaborate With NIDDK On Study Of Obeticholic Acid In Nonalcoholic Steatohepatitis
Mar 21, 2011: NasVax Announces Success Of Phase IIa Clinical Trial Of New Oral Immunotherapy For Fatty Liver Disease
Oct 14, 2010: Galmed Initiates Phase II Clinical Trial Of Aramchol For Treatment Of Fatty Liver Disease
Sep 21, 2010: NasVax Initiates Phase IIa Clinical Trial For Oral Anti-CD3 Immunotherapy
Jul 28, 2010: Intercept To Collaborate With NIDDK On Study Of INT-747 In Nonalcoholic Steatohepatitis
May 03, 2010: Raptor Announces Positive Phase IIa Results From Non-Alcoholic Steatohepatitis Study
May 03, 2010: Raptor Pharmaceutical Announces Phase IIa NASH Study Meets Primary Endpoints: Results Released At Digestive Disease Week Conference
Apr 29, 2010: Investigators Study Pioglitazone And Vitamin E for treatment of NASH
Mar 19, 2010: Trophos Completes Patient Enrolment In Phase III Efficacy Study Of Olesoxime In ALS
Nov 17, 2009: Enzo Biochem announces that it is ready to reveal EGS21 data
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Non-Alcoholic Steatohepatitis, H2 2011
Products under Development for Non-Alcoholic Steatohepatitis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Mochida Pharmaceutical Co., Ltd., H2 2011
Norgine Limited, H2 2011
Enzo Biochem, Inc., H2 2011
Immuron Limited, H2 2011
Phynova Group Ltd, H2 2011
Raptor Pharmaceuticals Corp., H2 2011
7TM Pharma A/S, H2 2011
Wellstat Therapeutics Corporation, H2 2011
Conatus Pharmaceuticals Inc., H2 2011
Obio Pharmaceutical Holdings Limited., H2 2011
Kalypsys, Inc., H2 2011
NasVax Ltd., H2 2011
Galmed International Ltd., H2 2011
Connexios Life Sciences Pvt. Ltd., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Non-Alcoholic Steatohepatitis Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2011
Products under Development for Non-Alcoholic Steatohepatitis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos